Chargement en cours...
Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment
Classic Hodgkin lymphoma (cHL) stands out as success story in the field of medical oncology, with multiagent chemotherapy with or without radiation leading to durable remission for most patients. Large-scale clinical trials during the past 40 years have sought to minimize toxicities while maintainin...
Enregistré dans:
| Publié dans: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Auteur principal: | |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
American Society of Hematology
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6913455/ https://ncbi.nlm.nih.gov/pubmed/31808838 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2019000030 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|